Optimization of cardiovascular risk factor management in patients with BCR:: ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and …
I Krecak, S Verstovsek, M Lucijanic - Annals of hematology, 2024 - Springer
The exact prognostic role of cardiovascular (CV) risk factors in patients with BCR:: ABL1
negative chronic myeloproliferative neoplasms (MPNs) remains unknown as it is often …
negative chronic myeloproliferative neoplasms (MPNs) remains unknown as it is often …
Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms
I Krečak, S Vestovšek… - Clinical Advances in …, 2023 - unirepository.svkri.uniri.hr
Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general
population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the …
population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the …
Hip and knee osteoarthritis in patients with chronic myeloproliferative neoplasms: a cross-sectional study
Background: Osteoarthritis (OA) is a progressive degenerative disease with an inflammatory
background. Chronic myeloproliferative neoplasms (MPN) are clonal hematopoietic …
background. Chronic myeloproliferative neoplasms (MPN) are clonal hematopoietic …
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety
L Masarova, J Mascarenhas, R Rampal, W Hu… - Cancer, 2025 - Wiley Online Library
The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was approved by the US Food and
Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have …
Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have …
[HTML][HTML] Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications
I Krecak, D Lekovic, I Arsenovic, A Bogdanovic… - Journal of clinical …, 2024 - mdpi.com
Background: This study aimed to evaluate the clinical and prognostic associations of the
systemic inflammatory index (SII) in polycythemia vera (PV) patients. SII integrates …
systemic inflammatory index (SII) in polycythemia vera (PV) patients. SII integrates …
[引用][C] Position paper: The time for cooperative group study of ropeginterferon alfa‐2b in young patients with myeloproliferative neoplasms is now
N Kucine, JA Jessup, TM Cooper… - Pediatric Blood & …, 2023 - Wiley Online Library
The BCR-ABL1-negative classical myeloproliferative neoplasms (MPNs) are clonal
disorders characterized by acquired mutations in hematopoietic stem cells that lead to …
disorders characterized by acquired mutations in hematopoietic stem cells that lead to …